Stevens R F
Department of Haematology and Oncology, Royal Manchester Children's Hospital, UK.
Eur J Cancer. 1991;27 Suppl 1:S20-2.
Emesis is a major problem for children receiving cancer chemotherapy. Three open non-comparative studies have been conducted to assess the safety and efficacy of ondansetron in children receiving a variety of chemotherapy regimens. Patients received various dosages of ondansetron, intravenously or intravenously plus orally, 8-hourly, during chemotherapy, followed by oral treatment 8-hourly for 3-5 days following chemotherapy. Complete control of emesis was achieved in 42-87% of children, and complete plus major control (0-2 emetic episodes) was achieved in 65-98% of children during their chemotherapy treatment, which varied from 1-8 days, and in 54-92% of children over the total study period. Ondansetron was effective in children receiving a wide variety of chemotherapy regimens. However, more intensive chemotherapeutic regimens and platinum drugs are associated with lower response rates. Ondansetron was well tolerated and none of the patients experienced extrapyramidal symptoms.
呕吐是接受癌症化疗的儿童面临的一个主要问题。已经开展了三项开放性非对照研究，以评估昂丹司琼在接受各种化疗方案的儿童中的安全性和疗效。患者在化疗期间每8小时静脉注射或静脉注射加口服不同剂量的昂丹司琼，化疗后每8小时口服治疗3至5天。42%至87%的儿童呕吐得到完全控制，在化疗期间（持续1至8天），65%至98%的儿童呕吐得到完全加主要控制（呕吐发作0至2次），在整个研究期间，54%至92%的儿童呕吐得到完全加主要控制。昂丹司琼对接受各种化疗方案的儿童有效。然而，更强效的化疗方案和铂类药物与较低的缓解率相关。昂丹司琼耐受性良好，没有患者出现锥体外系症状。
